SEC Form 4 · accession 0001140361-18-022477
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
May 7, 2018
Accepted (ET)
May 9, 2018 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 7, 2018 | S | 15,548 | $10.11 | D | 2,295,376 | D | |
| Common StockF3,F2 | May 8, 2018 | S | 26,557 | $10.03 | D | 2,268,819 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.33. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F2The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.
- F3Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.12. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.